MDGL.O
MDGL.O- Latest Trade
- trading lower--
- --
- --
- As of Feb 5 2023. Values delayed up to 15 minutes
- Day Range
- -- - --
- 52-Week Range
- -- - --
Latest News
- BusinessMadrigal leads race for NASH treatments after trial success, shares surge
Madrigal Pharmaceuticals' experimental drug met the main goals in a eagerly anticipated late-stage study, propelling it to the forefront in the race for the first approved treatment for patients with advanced liver scarring.
- BusinessIntercept's NASH drug fails late-stage trial, shares tumble
Intercept Pharmaceuticals Inc said on Friday its treatment for patients with advanced liver scarring due to non-alcoholic steatohepatitis (NASH) failed to meet the main goal of a late-stage study, sending its shares down as much as 21%.
- BusinessAkero's drug meets main goal in NASH trial, shares surge 120%
Akero Therapeutics Inc said on Tuesday its lead experimental drug met the main goal of a mid-stage study testing it as a treatment for a type of fatty liver disease that currently has no approved medicine on the market.
- MarketsGroupon, Moderna, Knightscope
The tech-heavy Nasdaq rose nearly 2% on Monday, but was still on track for its worst ever start to the year as investors shied away from stocks with lofty valuations amid aggressive rate hike bets and geopolitical tensions.
- MarketsNetflix, Boeing, Ocuphire Pharma
The tech-heavy Nasdaq rose 1% on Monday, but was still on track for its worst start to the year as investors shied away from stocks with lofty valuations amid aggressive rate hike bets and geopolitical tensions.
- MarketsKellogg, BlackBerry, Madrigal Pharmaceuticals
U.S. shares were set to open lower on Monday, with the tech-heavy Nasdaq on track for its worst start to the year as investors shied away from stocks with lofty valuations amid aggressive rate hike bets and geopolitical tensions.
- BusinessMadrigal's drug candidate reduces fatty liver in late-stage NASH trial
Madrigal Pharmaceuticals Inc said on Monday a late-stage trial showed that its experimental drug helped reduce liver fat and certain lipids in patients with non-alcoholic steatohepatitis (NASH), an inflammatory disease of the liver.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,862.90 | -- |
| Copper | 771.60 | 0.65% |
| Brent Crude Oil | 79.94 | -- |
| CBOT Soybeans | 1,532.00 | -- |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,136.48 | 1.04% |
| Euro STOXX 50 | 4,257.98 | 0.40% |
| FTSE 100 | 7,901.80 | 1.04% |
| Nikkei 225 | 27,509.46 | 0.39% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes